» Articles » PMID: 26074964

Evidence for a Specific Diabetic Cardiomyopathy: An Observational Retrospective Echocardiographic Study in 656 Asymptomatic Type 2 Diabetic Patients

Overview
Publisher Wiley
Specialty Endocrinology
Date 2015 Jun 16
PMID 26074964
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Aim. Our aim was to assess the prevalence of subclinical diabetic cardiomyopathy, occurring among diabetic patients without hypertension or coronary artery disease (CAD). Methods. 656 asymptomatic patients with type 2 diabetes for 14 ± 8 years (359 men, 59.7 ± 8.7 years old, HbA1c 8.7 ± 2.1%) and at least one cardiovascular risk factor had a cardiac echography at rest, a stress cardiac scintigraphy to screen for silent myocardial ischemia (SMI), and, in case of SMI, a coronary angiography to screen for silent CAD. Results. SMI was diagnosed in 206 patients, and 71 of them had CAD. In the 157 patients without hypertension or CAD, left ventricular hypertrophy (LVH: 24.1%) was the most frequent abnormality, followed by left ventricular dilation (8.6%), hypokinesia (5.3%), and systolic dysfunction (3.8%). SMI was independently associated with hypokinesia (odds ratio 14.7 [2.7-81.7], p < 0.01) and systolic dysfunction (OR 114.6 [1.7-7907], p < 0.01), while HbA1c (OR 1.9 [1.1-3.2], p < 0.05) and body mass index (OR 1.6 [1.1-2.4], p < 0.05) were associated with systolic dysfunction. LVH was more prevalent among hypertensive patients and hypokinesia in the patients with CAD. Conclusion. In asymptomatic type 2 diabetic patients, diabetic cardiomyopathy is highly prevalent and is predominantly characterized by LVH. SMI, obesity, and poor glycemic control contribute to structural and functional LV abnormalities.

Citing Articles

Understanding Diabetic Cardiomyopathy: Insulin Resistance and Beyond.

Binu A, Kapoor N Heart Int. 2025; 18(2):7-13.

PMID: 39885933 PMC: 11781369. DOI: 10.17925/HI.2024.18.2.2.


Impact of oxidative stress on myocardial performance in patients with diabetes: a focus on subclinical left ventricular dysfunction.

Oksen D, Aslan M BMJ Open Diabetes Res Care. 2024; 12(3).

PMID: 38886070 PMC: 11184181. DOI: 10.1136/bmjdrc-2024-004153.


Prevalence of diabetic cardiomyopathy in patients with type 2 diabetes in a large academic medical center.

Swiatkiewicz I, Patel N, Villarreal-Gonzalez M, Taub P BMC Med. 2024; 22(1):195.

PMID: 38745169 PMC: 11095003. DOI: 10.1186/s12916-024-03401-3.


Diabetic cardiomyopathy: a brief summary on lipid toxicity.

Ke J, Pan J, Lin H, Gu J ESC Heart Fail. 2022; 10(2):776-790.

PMID: 36369594 PMC: 10053269. DOI: 10.1002/ehf2.14224.


Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management.

Ceriello A, Catrinoiu D, Chandramouli C, Cosentino F, Dombrowsky A, Itzhak B Cardiovasc Diabetol. 2021; 20(1):218.

PMID: 34740359 PMC: 8571004. DOI: 10.1186/s12933-021-01408-1.


References
1.
Kamalesh M, Nair G . Disproportionate increase in prevalence of diabetes among patients with congestive heart failure due to systolic dysfunction. Int J Cardiol. 2005; 99(1):125-7. DOI: 10.1016/j.ijcard.2004.05.049. View

2.
Dawson A, Morris A, Struthers A . The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus. Diabetologia. 2005; 48(10):1971-9. DOI: 10.1007/s00125-005-1896-y. View

3.
Nguyen M, Cosson E, Valensi P, Poignard P, Nitenberg A, Pham I . Transthoracic echocardiographic abnormalities in asymptomatic diabetic patients: association with microalbuminuria and silent coronary artery disease. Diabetes Metab. 2011; 37(4):343-50. DOI: 10.1016/j.diabet.2010.12.006. View

4.
Litwin S . Diabetes and the heart: is there objective evidence of a human diabetic cardiomyopathy?. Diabetes. 2013; 62(10):3329-30. PMC: 3781487. DOI: 10.2337/db13-0683. View

5.
Fang Z, Prins J, Marwick T . Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev. 2004; 25(4):543-67. DOI: 10.1210/er.2003-0012. View